147 related articles for article (PubMed ID: 23847953)
1. [Study on inhibitory effect of combined administration of bear bile powder and cyclophosphamide on colorectal cancer liver metastasis by regulating tumor microenvironment].
Cui W; Liu S; Yang M; Zhang T; Cai L; Qiu SL; Zheng J; Miao YJ; Zhao LM; Du J
Zhongguo Zhong Yao Za Zhi; 2013 Apr; 38(7):1036-40. PubMed ID: 23847953
[TBL] [Abstract][Full Text] [Related]
2. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
3. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
5. [Changes and significance of peripheral blood platelet count in tumor shrinkage induced by a low dose of CTX in T739 mice].
Li ML; Jia YJ; Jiang MN; Shu XH; Li CG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jun; 24(6):567-9. PubMed ID: 18538085
[TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
7. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice.
Huyan XH; Lin YP; Gao T; Chen RY; Fan YM
Int Immunopharmacol; 2011 Sep; 11(9):1293-7. PubMed ID: 21530682
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer].
Zhou ZW; Wan DS; Wang GQ; Ren JQ; Lu ZH; Tang SX; Ye YL; Chen G; Lin SX
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):161-4. PubMed ID: 16555161
[TBL] [Abstract][Full Text] [Related]
11. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
12. Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide.
Tzai TS; Lin JS; Chow NH
J Surg Res; 1996 Oct; 65(2):139-44. PubMed ID: 8903460
[TBL] [Abstract][Full Text] [Related]
13. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
[TBL] [Abstract][Full Text] [Related]
16. [Influences of FVP1 on the curative and negative effects of CTX].
Yuan Q; Chen ZY; Yan MX
Zhongguo Zhong Yao Za Zhi; 2005 Jun; 30(12):933-5. PubMed ID: 16124615
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of immunosuppression induced by different doses of cyclophosphamide in normal mice].
Qi L; Song Y; Wang W; Cui W; Zhang X; Liu Z; Sun N; Li N
Wei Sheng Yan Jiu; 2010 May; 39(3):313-5, 325. PubMed ID: 20568461
[TBL] [Abstract][Full Text] [Related]
18. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
